论文部分内容阅读
目的:探讨莫西沙星(片剂)治疗阻塞性肺疾病急性加重期(AECOPD)的疗效及安全性。方法:124例AECOPD随机分为观察组和对照组,每组各62例。两组患者常规抗感染、平喘,吸氧、化痰,维持水电解质酸碱平衡等综合治疗外,对照组应用左氧氟沙星治疗,观察组应用莫西沙星(片剂)治疗,疗程均为8d。结果:观察组总有效率为91.9%,显著高于对照组75.8%,差异有统计学意义(P<0.05),且无明显不良反应。结论:莫西沙星(片剂)治疗AECOPD疗效显著,症状缓解迅速,且不良反应少,值得临床推广应用。
Objective: To investigate the efficacy and safety of moxifloxacin in the treatment of acute exacerbation of obstructive pulmonary disease (AECOPD). Methods: 124 AECOPD patients were randomly divided into observation group and control group with 62 cases in each group. Two groups of patients routine anti-infective, asthma, oxygen, phlegm, maintain the acid-base balance of water and electrolyte and other comprehensive treatment, the control group levofloxacin treatment, the observation group with moxifloxacin (tablets) treatment, treatment were 8d. Results: The total effective rate in the observation group was 91.9%, significantly higher than that in the control group (75.8%), the difference was statistically significant (P <0.05), and no obvious adverse reactions. Conclusion: Moxifloxacin (AECOPD) is effective in treating AECOPD with rapid response and less adverse reactions, which is worthy of clinical application.